Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE: Tezacaftor/Ivacaftor in CF Homozygous F508del
NCT02347657Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Tezacaftor/Ivacaftor with Placebo (2 arms). Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second at 24 weeks. Started Jan 2015; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02347657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347657.